Fragment Growing Kinase Targets

Almost half of the fragment-derived drugs that have entered the clinic target protein kinases. This reflects both the recent popularity of this class of targets [99] as well 

Drug and latest reported development Company Target 

Some of these drugs have been discontinued (e.g., SGX-523), and for others no development has been reported for some time (e.g., ABT-518). Drugs highlighted in bold are discussed in the text 

Multiple binding modes One binding mode crystallographic) 

---